<DOC>
	<DOCNO>NCT02937454</DOCNO>
	<brief_summary>Study Compare Ferric Carboxymaltose With Placebo Patients With Acute Heart Failure Iron Deficiency ( Affirm-AHF )</brief_summary>
	<brief_title>Study Compare Ferric Carboxymaltose With Placebo Patients With Acute Heart Failure Iron Deficiency</brief_title>
	<detailed_description>This randomise , double-blind , placebo-controlled Trial ( RCT ) . The 52 week observation period follow randomisation consider appropriate investigate primary endpoint recurrent HF hospitalisation CV death . To evaluate effect intravenous ferric carboxymaltose ( IV FCM ) iron deficient subject AHF , subject enrolled hospital stay ( Index hospitalisation ) acute care treatment index event stabilise . All subject continue receive establish standard therapy HF medical emergency treat accord local routine .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 Currently hospitalise episode acute heart failure ( AHF ) AHF primary reason hospitalisation . 2 . Subject iron deficient ( ID ) define serum ferritin &lt; 100 ng/mL 100 ng/mL ≤ serum ferritin ≤299 ng/mL transferrin saturation ( TSAT ) &lt; 20 % . 3 . Left ventricular ejection fraction &lt; 50 % ( assess document within 12 month prior randomisation ) . 4 . Male female age ≥18 year old . 5 . Subject ( legally acceptable representative ) provide appropriate write informed consent . 1 . Dyspnoea due noncardiac cause acute chronic respiratory disorder infection ( i.e. , severe chronic obstructive pulmonary disease , acute bronchitis , pneumonia , primary pulmonary hypertension ) . 2 . Temperature &gt; 38°C ( oral equivalent ) , active infective endocarditis , sepsis , systemic inflammatory response syndrome , active infection require antimicrobial treatment time Index hospitalisation . 3 . Clinical evidence acute coronary syndrome , transient ischemic attack stroke , within last 30 day prior randomisation . 4 . Coronaryartery bypass graft , cardiac resynchronisation therapy device implantation , percutaneous intervention ( e.g. , cardiac , cerebrovascular , aortic ; diagnostic catheter allow ) major surgery lead significant blood loss , include thoracic cardiac surgery , within last 3 month prior randomisation . 5 . Subject body weight &lt; 35 kg randomisation . 6 . Subject immediate need transfusion Hb &lt; 8 g/dL Hb &gt; 15 g/dL . 7 . Subjects know anaemia attribute ID ( e.g. , microcytic anaemia ) evidence iron overload ( e.g. , haemochromatosis ) disturbances utilisation iron . 8 . Subject know hypersensitivity study product administer know serious hypersensitivity parenteral iron product . 9 . Renal dialysis ( previous , current plan within next 6 month ) . 10 . Chronic liver disease ( include active hepatitis ) and/or alanine transaminase aspartate transaminase 3 time upper limit normal range . 11 . Subjects know hepatitis B surface antigen positivity and/or hepatitis C virus ribonucleic acid positivity . 12 . Subject pregnant ( e.g. , positive human chorionic gonadotropin test ) breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute Heart Failure</keyword>
	<keyword>Iron Deficiency</keyword>
</DOC>